Estrogen has been found to promote tumor growth in estrogen receptor-negative breast cancers and other cancers like melanoma and colon cancer by suppressing the immune system.

Invivyd's pemivibart, an investigational mAb, is being evaluated in the Phase 3 CANOPY trial for COVID-19 prevention in immunocompromised individuals and those at risk of exposure.

UCB's bepranemab, an anti-tau antibody, demonstrated encouraging results in a Phase 2a study for prodromal to mild Alzheimer's disease, warranting further investigation.

MoonLake Immunotherapeutics reported a net loss of $36.1 million for Q3 2024, driven by increased research and development expenses related to Sonelokimab (SLK).

ROME Therapeutics is presenting preclinical data on LINE-1 reverse transcriptase (RT) inhibitors at ACR Convergence 2024, highlighting their potential in treating autoimmune diseases.

Amgen's Uplizna demonstrated durable efficacy in patients with acetylcholine receptor antibody-positive generalized myasthenia gravis, with 72.3% of treated patients showing significant improvement in daily living activities versus 45.2% on placebo at 52 weeks.

NX-5948, a novel BTK degrader, shows a 77.8% overall response rate in patients with relapsed/refractory Waldenström macroglobulinemia (WM) in a phase 1a/b trial.

Pegcetacoplan significantly reduced proteinuria by 68% in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) compared to placebo.

Cybin has initiated its Phase 3 PARADIGM program to assess CYB003 as an adjunctive treatment for major depressive disorder (MDD).

The FDA has granted approval to olutasidenib for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adult patients with a susceptible IDH1 mutation.

A novel combination therapy of enzalutamide and talazoparib shows a statistically significant increase in overall survival rates for patients with late-stage prostate cancer.

Candel Therapeutics reported a net loss of $10.6 million for Q3 2024, with cash runway extending through Q1 2025, while R&D expenses saw a slight decrease.

The European Union's drug regulator recommends approval for Leqembi, developed by Eisai and Biogen, potentially becoming the first approved Alzheimer's treatment in the EU.

Cilcare has granted Shionogi an exclusive option to license global rights to two promising drug candidates (CIL001 and CIL003) for hearing disorders, receiving an upfront payment of €15 million with potential milestone payments reaching €400 million.

Amgen's stock experienced a downturn following the disclosure of phase 1 trial data for its anti-obesity drug candidate, MariTide, raising concerns about bone mineral density loss.

Indaptus Therapeutics reported a 26% decrease in operating expenses for Q3 2024, driven by the completion of certain manufacturing processes for Decoy20.

Over 60 mRNA cancer vaccines are currently in clinical trials, with the most advanced candidate, Moderna and Merck’s mRNA-4157, in Phase 3 for solid malignancies.

Monte Rosa Therapeutics anticipates Q1 2025 clinical data from its Phase 1 study of MRT-6160, a VAV1-directed molecular glue degrader for immune-mediated conditions.

Aroa Biosurgery's Endoform Natural demonstrated up to 8 weeks faster healing of venous leg ulcers compared to a leading reconstituted collagen dressing in a large real-world evidence study involving 830 patients across 223 wound care centers.

Pharmacosmos Group has successfully completed its acquisition of G1 Therapeutics for $7.15 per share, representing a 68% premium to G1's closing price before announcement and a total equity value of approximately $405 million.